Novartis' Inclisiran Grounded In The US By FDA Inspection Restrictions

 
• By Jessica Merrill

The US FDA issued a complete response letter for inclisiran, delaying the launch of the RNAi-based PCSK9 inhibitor for high cholesterol.

Storm at the airport. View of the airplane through rain drops.
FDA issued a CRL for Novartis' inclisiran • Source: Shutterstock

More from Cardiovascular

More from Therapy Areas